QTREX Quantum Ltd. (QTEXW) Aktienanalyse

QTREX Quantum Ltd., engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure and advanced connectivity solutions for the quantum computing industry in Israel and USA. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. It also offers HYLA blood sensor, which is designed to perform real-time sampling and analysis of key blood parameter measurements. In addition, The company offers cryogenic interconnects systems are generally built from multiple discrete components assembled and verified in a manual process. It also develops a monolithic interconnect architecture that integrates the conductor, radio-frequency dielectric, shielding, thermal management, and mechanical routing into a single engineered structure, designed to replace discrete, manually assembled cabling and support higher channel density and reliability. In addition, It offers AME Platform, provides the manufacturing foundation for our quantum connectivity development efforts and also operates as a commercial business serving customers across aerospace, missile, defense, and advanced electronics sectors. The company was formerly known as Inspira Technologies Oxy B.H.N. Ltd. and changed its name to QTREX Quantum Ltd. in May 2026. QTREX Quantum Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.

Die Unternehmensbeschreibung wird auf Englisch angezeigt.